myocardial ischemia reperfusion injury
Conditions
Interventions
Treatment group B:On the basis of standardised western medical treatment, Yixinfang granules were given preoperatively and postoperatively.
control group:Pre- and postoperative placebo (with 10% Yixinfang granules) was given on the basis of standard Western medicine regimens.
Treatment group A:On the basis of standardised western medicine treatment, placebo was given preoperatively, and Yixinfang granules were given postoperatively.
Sponsors
Shuguang Hospital affiliated with Shanghai University of TCM
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1) Age 18-85 years old gender unrestricted; 2) STEMI patients suitable for coronary artery stent implantation; 3) Patients diagnosed with Qi deficiency and blood stasis syndrome in Traditional Chinese Medicine; 4) Voluntary participants who have signed the informed consent form; 5) Patients who have not received Yixin Formula treatment before. All five conditions must be met for inclusion in the clinical study.
Exclusion criteria
Exclusion criteria: 1)Patients with cardiogenic shock 2) patients with combined severe pulmonary insufficiency; 3) patients with combined severe primary diseases of liver brain kidney and haematopoietic system and psychiatric patients; 4) People with controversial identification and typing in traditional Chinese medicine; 5)Pregnant or preparing for pregnancy breastfeeding women; 6) Known allergy to such drugs and those with severe allergies; 7)Patients who have participated in other clinical drug trials within the last 3 months; 8)Inability or unwillingness to sign the informed consent form. All of the above eight No can be included in the clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of TCM symptoms;Clinical endpoint events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cardiac enzymes;echocardiographic parameters;Plasma type B brain natriuretic peptide;electrocardiogram;TNF-a;superoxide dismutase;Cardiac troponin I;Evaluation of coronary blood flow by TIMI flow grading method;Amino-terminal brain natriuretic peptide precursor;S1P;IL-6;IL-1;nitric oxide; | — |
Countries
China
Contacts
Public ContactRong Jingfeng
Shuguang Hospital affiliated with Shanghai University of TCM
Outcome results
None listed